Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115491) titled 'The influence of CD27-CD21+ B cells and IgA plasma cell changes in patients with IgA nephropathy on the prognosis of treatment with Nefecon' on Dec. 26, 2025.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University
Condition:
IgA nephropathy
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-01-01
Target Sample Size: Observation group:96;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=293088
Disclaimer: Curated by HT S...